Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation

Thrombosis and Haemostasis

Volumn 75, Issue 1, 1996, Pages 76-82

  Sundaram, Sumuk ^d   Gikakis, Nicolas ^c   Hack, C Erik ^b   Niewiarowski, Stefan ^a   Edmunds Jr , L H ^c   Rao, A Koneti ^a   Sun, Ling ^d   Cooper, S L ^d   Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL LABORATORY   (Netherlands)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Delaware   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; BETA THROMBOGLOBULIN; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOPEPTIDE A; HEPARIN; KALLIKREIN; LEUKOCYTE ELASTASE; MARKER; NAFAMSTAT MESILATE; PROTEINASE INHIBITOR; THROMBIN;

ARTICLE; CARDIOPULMONARY BYPASS; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME RELEASE; EXTRACORPOREAL CIRCULATION; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; LEUKOCYTE ACTIVATION; NEUTROPHIL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK; SIMULATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TIME;

EID: 0030034663     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650224     Document Type: Article

References (33)

1. Edmunds LH. Why cardiopulmonary bypass makes patients sick: Strategies to control the blood-synthetic surface interface. Adv Cardiac Surg 1995; 6: 131-67.
2. Colman RW. Platelet and neutrophil activation in cardiopulmonary bypass. Ann Thorac Surg 1990; 49: 32.
3. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
4. Neville WE, Kontaxis A, Gavin T, Clowes GH. Postperfusion pulmonary vasculitis. Arch Surg 1963; 86: 126.
5. Ratliff NB, Young WG, Hackel DB, Mikat E, Wilson JW. Pulmonary injury secondary to extracorporeal circulation. J Thorac Cardiovasc Surg 1973; 65: 425.
6. 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-71.
7. Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-202.
8. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983; 72: 1672-77.
9. Blackstone EH, Kirklin JW, Stewart RW, Chenoweth DE. The damaging effects of cardiopulmonary bypass. In: Prostaglandins in Clinical Medicine: Cardiovascular and Thrombotic Disorders. Wu KK, Roxy EC, eds. Yearbook Medical Publishers, Inc., Chicago, 1982: 355-69.
10. Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Relly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds LH Jr, Colman RW. Selective inhibitors of kallikrein alter the release of human neutophil elastase during extracorporeal circulation. Am J Physiol 1995; 268: H1352-H7.
11. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-91.
12. Fujii S, Hitomi Y. New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661: 342-5.
13. Murakawa M, Okamura T, Shibuya T, Harada M, Otsuka T, Niho Y. Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation. Ann Hematol 1992; 64: 249.
14. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: A regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376.
15. Tanaka K, Kondo C, Takagi I, Sato T, Yada I, Yuasa H, Kusagawa M. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. ASAIO J 1993; 39: M545.
16. Kinugasa E, Akizawa T, Nakashima Y, Wakasa M, Koshikawa S. Nafamostat as anti-coagulant for membrane plasmapheresis in high bleeding risk patients. Int J Artif Organs 1992; 15: 595.
17. Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3: 365.
18. Wintrobe MH. Principles and techniques of blood examination. In: Clinical Hematology. Lea & Febiger, Philadelphia, 1967: 410.
19. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
20. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH, Colman RW. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-30.
21. Hack CE, Hannema AJ, Eerenberg Belmer AJ, Out TA, Aalberse RC. A Cl-inhibitor-complex assay (INCA): a method to detect Cl activation in vitro and in vivo. J Immunol 1981; 127: 1450-3.
22. Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt Bersma RJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-CI(-)-inhibitor and kallikrein-CI(-)-inhibitor complexes in sepsis. Blood 1988; 72: 1841-8.
23. Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski AZ. Anti-heparin proteins secreted by platelets: Purification, characterization and radioimmunoassay. Blood 1979; 53: 47.
24. Amiral J, Walenga JM, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Haemost 1984; 10: 228.
25. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against synthetic peptide. Thromb Haemost 1991; 65: 153.
26. Meri A, Aronen M, Leijala M. Complement activation during cardiopulmonary bypass in children. Complement 1988; 5: 46.
27. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds KLH Jr. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106 1-10.
28. Selak M. Cathepsin G and thrombin: evidence of two different platelet receptors. Biochem J 1994; 297: 269.
29. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepato-Gastroenterology 1992; 39: 59.
30. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD Complement and the damaging effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 86: 845.
31. Finn A, Rebuck N, Moat N. Neutrophil activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 1746.
32. Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236.
33. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993; 72: 1075.